Birchview Capital’s Grace Therapeutics GRCE Stock Holding History

Birchview Capital’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272K	Buy	120,000 +70,000	+140%	+$194K	0.13%	62
2026 Q1	$232K	Buy	+50,000	New	+$196K	0.13%	66

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Birchview Capital's GRCE Position: Q2 2026 in Review

Birchview Capital increased its Grace Therapeutics (GRCE) stake by 140% in Q2 2026, buying an estimated $194K and bringing the position to 120,000 shares worth $272K. The position accounts for 0.13% of the portfolio, ranked #62.

Birchview Capital first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Birchview Capital held 120,000 shares of Grace Therapeutics worth $272K as of Q2 2026.
Birchview Capital bought 70,000 Grace Therapeutics shares in Q2 2026, an estimated $194K.
Grace Therapeutics made up 0.13% of Birchview Capital's portfolio in Q2 2026, its #62 holding.
Birchview Capital first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.